In this phase I trial, Lai and colleagues evaluated the safety and toxicity of EGFR antisense DNA therapy in 20 patients with advanced squamous-cell carcinoma of the head and neck. All patients ...

Antisense suppression of IGF-I receptors in ... Oligonucleotide sequences corresponded to DNA sequences complementary to the coding region of the IGF type I receptor mRNA 46, with dU substituted ...

Wave Life Sciences’ Phase II open-label trial investigating its disease-modifying drug for boys living with Duchenne Muscular ...

These informational drugs, known as antisense therapies, chemically modify genetic sequences to reach specific targets and block disease-associated mRNA. Agrawal likens these therapies to “genetic ...

Among the DNA repair genes identified ... These neurons were then treated with an antisense oligonucleotide (ASO) that binds to MSH3 mRNA, reducing its expression, and changes in CAG repeat ...